Agracetus Inc. deal

The W. R. Grace subsidiary will exclusively produce Bristol-Myers Squibb's BR96-doxorubicin conjugate in transgenic plants. BR96, which is in Phase I trials, is Bristol-Myers' lead therapeutic monoclonal antibody.

Agracetus will used its Accell gene delivery system to transform corn and soybean with genetic constructs, directing the production of BR96 in the seeds. After the harvest, the recombinant antibody will be recovered from the seeds using protein extraction and separation techniques. ...